Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies have transformed non-small-cell lung cancer (NSCLC) management, improving survival.
• Rapid discoveries of oncogenic drivers necessitate continuous updates in clinical practice.
• Actionable mutations present opportunities for personalized treatment strategies in NSCLC.

Purpose of the Study:

• To review the evolving landscape of targeted therapies for actionable mutations in NSCLC.
• To highlight recent advancements in KRAS-targeted treatments, including non-G12C mutations and pan-RAS inhibitors.
• To discuss emerging therapies for EGFR, ALK, MET, HER2, RET, ROS1, FGFR, and TROP-2 alterations.

Main Methods:

• Literature review of recent clinical trials and research publications.
• Analysis of therapeutic strategies for specific oncogenic drivers in NSCLC.
• Synthesis of information on established and novel targeted agents.

Main Results:

• Significant progress in KRAS-targeted therapies, including non-G12C and pan-RAS inhibitors.
• Established standards of care for EGFR and ALK alterations continue to evolve.
• Emerging therapies for MET, HER2, RET, ROS1, FGFR, and TROP-2 show promise.

Conclusions:

• The field of targeted therapy for NSCLC is rapidly advancing, offering more treatment options.
• KRAS and TROP-2 represent key areas of recent development.
• Personalized medicine approaches are crucial for optimizing NSCLC patient outcomes.